This fall marks the 50th anniversary of a fateful meeting at a deli in Hawaii where two scientists, both in town for a conference, collaborated over corned beef sandwiches on the idea that would give rise to the modern biotechnology industry, now with a global market share topping $1 trillion,according to one recent global analysis.The story of scientists Stanley Cohen and Herbert Boyer is a classic tale of American innovation. Their invention of an efficient, reliable method for gene transfer spawned a whole new sector of companies, whose products range from lifesaving drugs and disease resistant plants to climate-friendly fuels and materials.

Fast forward to 2022: Biotechnology has become a key tool for improving our quality of life, from producing more effective cleaning products, to better vaccines that support wide public health. It is also a science representing extraordinary possibilities for solving complex challenges such as climate-change, food insecurity, and public health, economic development.

Imagine climate-friendly countertops made from fish scales and turning banana peels or avocado seeds into bioplastic products. Luxury furniture made out of fungus and cell phones created from plants and powered by engineered microbes. Transforming food waste into everything from organic fertilizers to construction materials. Even 3D printed organs for transplant.

The future of biotechnology marries imagination with innovation and will open manufacturing pipelines and job opportunities across the country.

For all the important advances that were made in the U.S. biotechnology space during the past few decades, it also is the case that global competition has increased, as well, during the same era.

Countries around the world are making strategic investments, developing ambitious policy roadmaps, and offering economic incentives with the goal of establishing national biotechnology industries that could surpass the United States. According to Forbes, China has invested more than $500 billion in biotechnology and biomanufacturing over the last six years, and has become dominant in controlling the bio-based supply chain. India has launched a major push to become a global biomanufacturing hub. The European Union has released a Bioeconomy Strategy, which includes prioritizing bio-based industries and unlocking new markets. While the United States still holds the leading edge in biotechnology innovation and production, we can no longer take our market-leading role for granted.

To accelerate the transformation of biotechnology advancements into solutions for real world problems, the Biden-Harris administration has launched the Biotechnology and Biomanufacturing Initiative through a new executive order, which has the potential to improve the everyday lives of all people.

And, at the White House Office of Science and Technology policy, we believe in the power of science and technology to improve health, prosperity, and security, but we know those goals are only truly achieved when the benefits are shared equitably. Thats why this initiative helps ensure that the biotechnology invented here leads to products that are made here, using the biomass from corn in Iowa to tobacco in North Carolina to fish in Alaska grown in communities across the country.

This is a chance to sharpen the nations cutting edge of life science research and development through investments that not only advance our innovative leadership, but also build in principles of equity, ethics, safety, and security from the very outset.

Even as we fulfill the promise of a bio-based future, we must always be aware of the perils, including complex ethical dilemmas and biosecurity concerns, and the best way to make sure we mitigate that risk is through global leadership and example. To minimize the risks of unintended consequences from these powerful tools, the U.S. bioeconomy must model the norms of biosafety, biosecurity, and wise and equitable governance technology governance that wed like to see embraced worldwide. That means committing as a whole government to improve clarity and efficiency of regulatory process for biotechnology products. It means engaging with stakeholders domestically and internationally to identify areas of ambiguity, publishing plain-language clarification and information about which bodies are responsible for oversight, providing timelines to implement regulatory reform, and enhancing biotechnology government cooperation.

If we want to corner the market on bioproducts we havent even imagined yet, we cannot afford to leave any talent behind, which is why we are expanding training and educational opportunities for the biotechnology and biomanufacturing workforce, with an emphasis on advancing racial and gender equity and inclusion of underserved communities.

In signing the bipartisan CHIPS and Science Act, President Biden acknowledged the leap-forward it represents, specifically, its historic investment in innovation aimed squarely at the public interests. He noted, We are the United States of America, a singular place of possibilities.

Harnessing the possibilities of biotechnology, to the fullest extent possible will make our country healthier, cleaner, and more secure. If you thought the last 50 years of the biotech revolution were exciting, wait until you see what comes next.

Carrie D. Wolinetz, Ph.D. is the Deputy Director for Health & Life Sciences for the White House Office of Science and Technology Policy (OSTP), where she helps advance priority presidential efforts including pandemic preparedness, health systems & health equity, and accelerating innovation to patients.

More here:
How the US can harness the possibilities of biotechnology - The Hill

Cynthia Reinhart-King, Cornelius Vanderbilt Professor of Engineering and professor of biomedical engineering, was among a handful of national experts invited to participate in the White House Summit on Biotechnology and Biomanufacturing on Sept. 14 in Washington, D.C.

The event, co-led by the National Economic Council, marked the launch of an initiative to develop bio-based solutions to global challenges ranging from food security and climate change to health security and supply chain disruptions.

Heads of U.S. government agencies and members of Congress, as well as leaders from industry, academic institutions and nongovernmental organizationsrepresenting a range of bio sectors and regionsattended the summit. The panel comes on the heels of two major federal initiatives: the signing of the CHIPS and Science Act of 2022, which provides billions of dollars in new funding to boost domestic research and manufacturing of semiconductors in the U.S.; and the creation of Advanced Research Projects Agency for Health at the National Institutes of Health, which will fund high-risk, high-reward, use-inspired biomedical and biotechnology research.

The significant investment this administration is making in biotechnology and the bioeconomy is a landmark and will ensure that the U.S. continues to lead in technological and manufacturing innovation, said Reinhart-King, who is also senior associate dean for research at the School of Engineering. I look forward to continued discussions and engaging in bio-based research that benefits all Americans and addresses the global issues we face today.

Reinhart-King, a cellular bioengineer who is president-elect of the Biomedical Engineering Society, has contributed to scientific breakthroughs in understanding tumor formation. She was one of the first to show how the matrix, or the noncellular glue in all tissues and organs, can stiffen when a tumor forms, promote tumor growth and interfere with the effectiveness of cancer treatments.

Padma Raghavan, Vanderbilts vice provost for research and innovation, said Reinhart-Kings invitation to take part in the summit speaks to her high standing in the field and offers recognition of her pathbreaking research.

In the last year alone, Vanderbilt has committed over $60 million dollars to advance bioscience and biotechnology solutions with significant investments on the horizon to drive Vanderbilts transformative national model for bio-based innovation, Raghavan said. Vanderbilts investments demonstrate the power of universities to produce cutting-edge biotech and biomanufacturing research with high economic and social impact, addressing global challenges in health security, national defense and climate change.

Original post:
Preeminent engineering researcher takes part in national summit on biotechnology and biomanufacturing - Vanderbilt University News

In brief

By National Law No. 27,685 ("Law"), published on 16 September 2022, Law No. 26,270 was amended, expanding throughout the entire national territory the promotion regime for the development and production of modern biotechnology and nanotechnology. The regime will be in force up to 31 December 2034.

The Law set forth the following tax benefits: (i) the accelerated amortization of the capital goods, special equipment, and parts or elements forming those new goods, which were acquired for the project; (ii) the anticipated refund for the VAT corresponding to the goods acquired for the project; and (iii) the granting of a tax credit bond equivalent to 50% of expenses paid for hiring investigative and development services from institutions that are part of the national public system of science, technology and innovation. The tax credit bond will be valid for 10 years and it will only be transferable once.

In focus

The Law includes the concept of nanotechnology in the definition of "Modern Biotechnology", which means every technological application based on rational knowledge and scientific principles that derive from biology, biochemistry, microbiology, bioinformatics, molecular biology and genetic engineering, or that uses live organisms or parts of them, either for the production of goods and services, or for the substantial improvement of products and productive processes.

The Law set forth the following tax benefits:

Click here to download the Spanish version.

Content is provided for educational and informational purposes only and is not intended and should not be construed as legal advice. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee similar outcomes. For more information, please visit:www.bakermckenzie.com/en/client-resource-disclaimer.

Read more:
Argentina: Promotion of modern biotechnology and nanotechnology - Lexology

Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis

Novel combination strategy designed toreduce HDV viremia and block viral entry

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.

VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) that diminishes the level of all HBV proteins in vitro, including hepatitis B surface antigen, a protein necessary to create infectious HDV virions. VIR-3434 is an investigational hepatitis B surface antigen targeting monoclonal antibody designed to remove both HBV and HDV virions from the blood and block the entry of these viruses into liver cells. VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial. Previously reported results from Part A of the MARCH trial demonstrated that the combination of VIR-3434 and VIR-2218 resulted in an approximate 3 log decline in hepatitis B surface antigen (HBsAg).

Globally, more than 12 million people are living with HDV, and with no approved therapies available in the United States, there is an urgent need for the development of novel treatment strategies that will improve outcomes for patients, said Carey Hwang, M.D., Ph.D., Virs senior vice president, clinical research, head of chronic infection. Recent research suggests that reducing HDV viremia, by preventing virion formation as well as facilitating virion removal, in conjunction with blocking HDV virion entry into liver cells could be effective in suppressing chronic HDV infection. The initiation of SOLSTICE, our first clinical trial in HDV, is an important milestone as we advance our broad therapeutic portfolio for viral hepatitis, which also includes the pursuit of a functional cure for chronic HBV infection.

Design of the Phase 2 SOLSTICE TrialThe multi-center, open-label Phase 2 SOLSTICE trial is designed to evaluate the safety, tolerability, and efficacy of VIR-2218 and VIR-3434 in adult patients (age 18 to 69) with chronic HDV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Depending on the cohort, trial participants will receive multiple doses of VIR-2218 and VIR-3434 as either monotherapy or in combination administered via subcutaneous injection for up to 88 weeks. The primary endpoints of the trial are the proportion of study participants achieving either a 2log10 decrease in HDV RNA compared to baseline, or HDV RNA less than the limit of quantification and normalization of alanine transaminase (ALT) at Week 24, as well as the proportion of participants with treatment-emergent adverse events and serious adverse events. Vir expects initial data from the SOLSTICE trial in 2023.

About Chronic Hepatitis DChronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV). An estimated 12 million patients globally are infected with HDV, representing approximately 5% of those infected with HBV. HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression toward hepatocellular carcinoma and liver-related death.

About Chronic Hepatitis BChronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality. Approximately 300 million people around the world are living with HBV and approximately 900,000 of them die from associated complications each year. These patients are significantly underserved by existing therapies with low functional cure rates, lifelong daily therapy and poor tolerability. Vir is working to achieve a functional cure for the millions of people with HBV around the world through its broad and differentiated portfolio.

About VIR-2218VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the Companys collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About VIR-3434VIR-3434 is an investigational subcutaneously administered antibody designed to block entry of HBV and HDV viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencors Xtend and other Fc technologies, has been engineered to potentially function as a T cell vaccine against HBV and HDV in infected patients, as well as to have an extended half-life.

About Vir BiotechnologyVir Biotechnologyis a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, plan, potential, aim, expect, anticipate, promising and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of VIR-2218 and VIR-3434 in combination to treat chronic HDV and HBV infection; the potential benefits of VIR-2218 and VIR-3434; Virs plans and expectations for its HDV and HBV portfolios; the initial results of the MARCH trial; the timing for and design of the Phase 2 SOLSTICE trial; the treatment of HDV and HBV; and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including risks that Vir may not fully enroll the Phase 2 SOLSTICE trial or it will take longer than expected; unexpected safety or efficacy data or results observed during the Phase 2 SOLSTICE trial or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; successful development and/or commercialization of alternative product candidates by Virs competitors; changes in expected or existing competition; delays in or disruptions to Virs business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Link:
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphatecompetitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib has been tested in clinical trials in patients with metastatic cancers including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia.

Under the terms of the agreement, Puma will assume sole responsibility for the global development and commercialization of alisertib. Takeda will receive an upfront license fee of $7 million and is eligible to receive potential future milestone payments of up to $287.3 million upon Pumas achievement of certain regulatory and commercial milestones over the course of the agreement, as well as tiered royalty payments for any net sales of alisertib.

Puma initially intends to focus the development of alisertib on the treatment of patients with metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer and small cell lung cancer. In ER-positive HER2-negative breast cancer, alisertib has previously been tested in a Phase II clinical trial as a single agent (Lancet Oncology 2015), in a Phase II randomized clinical trial as a single agent compared to a combination with fulvestrant (SABCS 2020) and in a Phase II randomized clinical trial in combination with paclitaxel compared to paclitaxel monotherapy (JAMA Network Open 2021). In triple-negative breast cancer, alisertib has previously been tested in a Phase II clinical trial as a single agent (Lancet Oncology 2015) and in a randomized clinical trial in combination with paclitaxel compared to paclitaxel monotherapy (JAMA Network Open 2021). Alisertib has demonstrated meaningful clinical activity in these populations and most notably in ER-positive breast cancer patients who have been previously treated with a CDK4/6 inhibitor (JAMA Network Open 2021). Alisertib has also been previously tested in small cell lung cancer in a Phase II clinical trial as a single agent (Lancet Oncology 2015) and in a Phase II randomized clinical trial in combination with paclitaxel compared to paclitaxel monotherapy (Journal of Thoracic Oncology 2020).

There continues to be a need for new drugs for the treatment of metastatic ER- positive, HER2-negative breast cancer and triple negative breast cancer, said Joyce A. OShaughnessy, M.D., the Celebrating Women Chair in Breast Cancer Research at Baylor University Medical Center, Texas Oncology, and Chair of Breast Cancer Research for the US Oncology Network in Dallas, Texas. The results from the clinical trials of alisertib in these two indications are encouraging and suggest that the drug may be able to provide a clinical benefit to these patient populations, and, due to its novel mechanism, alisertib may be able to provide a benefit in patients who have developed resistance to other treatments modalities, said Dr. OShaughnessy.

Treatment options for patients with small cell lung cancer that has progressed on or after platinum-based chemotherapy are limited, and there is an urgent need for new drugs to treat this patient population, said Taofeek K. Owonikoko, MD, PhD, Chief of the Division of Hematology/Oncology and Associate Director for Translational Research and Co-Leader of the Cancer Therapeutics Program at the UPMC Hillman Cancer Center. The results from the clinical trials of alisertib in small cell lung cancer suggest that the drug may represent a potentially promising treatment option for these patients and more specifically for patients with molecularly defined tumors that are likely to respond to an aurora kinase A inhibitor such as alisertib, said Dr. Owonikoko.

Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma stated, We are pleased to be able to complete this licensing agreement with Takeda for alisertib. To date, alisertib has demonstrated strong evidence of antitumor activity, both as a single agent and in combination with other anticancer drugs, in patients with metastatic ER-positive and triple negative breast cancer, as well as in small cell lung cancer. We look forward to the continued development of alisertib.

Puma will host a conference call today at 2:00 p.m. PDT/5:00 p.m. EDT to discuss the alisertib licensing agreement. The call may be accessed by dialing (877) 709-8150 (domestic) or (201) 689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the Puma Biotechnology Conference Call. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of the call and will be archived on Pumas website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the development and commercialization of alisertib. All forward-looking statements involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent reports. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

See original here:
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora...

There are many foundations and charities which aim to tackle health conditions through funding medical research to develop better treatment options, improve patient outcomes and quality of life.

People often bequest money in their will to these organisations, donate after a loved one has been struck down by a particular illness or at funerals ask for donations to a an organisation in lieu of traditional flowers.

And while these organisations do great work, what about considering investing directly in medical companies for the greater good? Biotechnology investing is one sector which stands out for not only potential to deliver quality returns but also contribute positively to society.

Australias biotech representative body AusBiotech CEO Lorraine Chiroiu told Stockhead many of us unfortunately have a personal connection to catastrophic disease and, motivated by our experiences, are seeking avenues to put our philanthropic and investment dollars where we can make a meaningful and sustainable difference.

AusBiotech is receiving increasing enquiries from people who want to gift, bequeath or invest in a way that gives the best chance of new medical treatments and cures making their way to people experiencing disease, she said.

For example, we recently received a call from a father whose only son had passed away from cancer. Nobly, he wanted to make a purposeful investment into a company working to provide treatment for the disease that took his son in the hope that other families wouldnt have to go through the same suffering as his family.

Indeed many biotech companies have been founded by grieving family or friends that are passionate about finding a cure for a disease that took their loved one too soon.

Chiroiu said biotechnology companies are the vehicles that move medical research along the translation and commercialisation pathway to patients.

Companies operating in the life science and medtech sectors are in a unique position where business foundations are often influenced by a strong value-driven purpose one that offers positive social impact as the company develops life-saving and life-enhancing technologies.

Focusing clearly on patient impact, social good is codified into biotech companies DNA and are a great avenue for ethical investors to consider diversifying their portfolio.

She said we are living in an age of profound acceleration in medicinal discoveries and healthcare options, as well as a time that the Covid-19 pandemic has brought biotechnology especially in the form of vaccines into sharp focus.

As we emerge from the pandemic, the chronic health challenges and increasing burdens of disease associated with ageing populations around the world has many of us wondering how we can help move medical research from the bench to the bedside the answer is via business, she said

Australias biotech industry is on a strong growth trajectory, through substantially increasing numbers of organisations. Figures released by AusBiotech show the sector has grown 43% since 2019 and 60% since 2017.

Amid a thriving and expanding biotech industry in Australia, feeding the need for commercialisation, clinical development and growth is key and the diversity of investment sources remains a pressing issue, Chiroiu said.

Capital is the lifeblood of these companies and in response to this increasing need, AusBiotech has bolstered its investment program with a goal that Australian and overseas investors increasingly see Australian life sciences research and small-to-medium enterprises as viable and attractive investment options.

Global X head of investment strategy Blair Hannon told Stockhead biotechnology investing is well positioned to tick the boxes of environmental, social and governance (ESG) considerations of both institutional and retail investors.

For environmentally minded investors, the biotech industry has a low carbon footprint as most work is research-driven and not energy-intensive and as such, adding biotech exposure can help lower the average carbon footprint of a portfolio, Hannon said.

The biotech industry is highly regulated as measured by the S&P Biotechnology Select Industry Index and is free of any violators of the UN Global Compact (UNGC), which is a widely-followed benchmark of corporate good behaviour.

Hannon said alongside many other sectors, biotechs are striving towards ESG targets. Whilst a diversified biotech ETF such as its S&P Biotech ETF (ASX:CURE) is not explicitly tracking an ESG framework, Hannon noted many biotech companies within the fund focus on social good as their technology aims to aid people from all walks of life with disease treatments or even eradication.

Prescient Therapeutics (ASX:PTX)CEO and managing director Steven Yatomi-Clarke told Stockhead bringing life-changing therapies to patients is an incredibly challenging undertaking that requires resources and resilience.

PTX is at the forefront of game-changing personalised cancer treatments with a strong pipeline of promising therapies. The company has a growing list of collaborations with leading cancer organisations globally including Peter McCallum Cancer Centre, University of Texas MD Anderson Cancer Center, Yale, Oxford and UPenn.

Companies brave enough to take on this challenge call on investors to fund the research and development at least, until they become profitable, he said.

But at Prescient, when we accept a dollar from an investor, we are focussed on growing that into more than one dollar.

He said in the last two years, Prescient has spent around $8m of shareholder funds, but through consistent delivery of milestones and progress, the company has translated this $8m into over $100m of shareholder value.

So shareholders have enjoyed a handsome financial return, but additionally, they can be satisfied in knowing that their investment has resulted in incredibly exciting progress to create therapies that we believe are going to change lives.

AusBiotech is aiming to educate potential investors in life sciences companies about the unique ecosystem, through in-person events such as its AusBioInvest 2022 in Perth in October as well as plain English resources including The Guide to Life Sciences Investing,

At Stockhead, we tell it like it is. While Prescient Therapeutics is a Stockhead advertiser, it did not sponsor this article.

Get the latest Stockhead news delivered free to your inbox.

"*" indicates required fields

It's free. Unsubscribe whenever you want.

You might be interested in

Original post:
Biotechnology investing for the social good making money and a difference - Stockhead

DUBLIN--(BUSINESS WIRE)--Sep 22, 2022--

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm%96 v=@32= (9:E6 q:@E649?@=@8J |2C<6E :D 6DE:>2E65 E@ 36 H@CE9 &$s a_g >:==:@? 😕 a_aa[ 2?5 😀 6IA64E65 E@ C6249 &$s ac`]be >:==:@? 3J a_af[ 8C@H:?8 2E 2 rpv# @7 b]_aT]k^Am

kAm|2C<6E $68>6?E2E:@?k^Am

kAm%96 v=@32= (9:E6 q:@E649?@=@8J |2C<6E :D D68>6?E65 32D65 @? !C@5F4E[ pAA=:42E:@?[ 2?5 v6@8C2A9J]k^Am

kF=mk=:mqJ !C@5F4E[ E96 >2C<6E :D 4=2DD:7:65 :?E@ q:@7F6=D[ q:@>2E6C:2=D[ q:@496>:42=D[ 2?5 x?5FDEC:2= t?KJ>6D]k^=:mk=:mqJ pAA=:42E:@?[ E96 >2C<6E :D 4=2DD:7:65 :?E@ r2C5:@G2D4F=2C[ }6FC@G2D4F=2C[ 2?5 &C@=@8J]k^=:mk=:mqJ v6@8C2A9J[ E96 >2C<6E :D 4=2DD:7:65 :?E@ p>6C:42D[ tFC@A6[ |:55=6t2DE U2>Aj p7C:42 2?5 pD:2!24:7:4]k^=:mk^F=m

kAmr@F?EC:6D $EF5:65k^Am

kF=mk=:mp>6C:42 WpC86?E:?2[ qC2K:=[ r2?252[ r9:=6[ r@=@>3:2[ |6I:4@[ !6CF[ &?:E65 $E2E6D[ #6DE @7 p>6C:42DXk^=:mk=:mtFC@A6 WpFDEC:2[ q6=8:F>[ s6?>2C<[ u:?=2?5[ uC2?46[ v6C>2?J[ xE2=J[ }6E96C=2?5D[ }@CH2J[ !@=2?5[ #FDD:2[ $A2:?[ $H656?[ $H:EK6C=2?5[ &?:E65 z:?85@>[ #6DE @7 tFC@A6Xk^=:mk=:m|:55=6t2DE 2?5 p7C:42 Wt8JAE[ xDC26=[ "2E2C[ $2F5: pC23:2[ $@FE9 p7C:42[ &?:E65 pC23 t>:C2E6D[ #6DE @7 |tpXk^=:mk=:mpD:2!24:7:4 WpFDEC2=:2[ q2?8=256D9[ r9:?2[ x?5:2[ x?5@?6D:2[ y2A2?[ |2=2JD:2[ !9:=:AA:?6D[ $:?82A@C6[ $@FE9 z@C62[ $C: {2?<2[ %92:=2?5[ %2:H2?[ #6DE @7 pD:2!24:7:4Xk^=:mk^F=m

kAm%96 r@>A6E:E:G6 "F25C2?Ek^Am

kAm%96 C6A@CE :?4=F56D E96 r@>A6E:E:G6 "F25C2?E[ 2 AC@AC:6E2CJ E@@= E@ 2?2=JK6 2?5 6G2=F2E6 E96 A@D:E:@? @7 4@>A2?:6D 32D65 @? E96:C x?5FDECJ !@D:E:@? D4@C6 2?5 |2C<6E !6C7@C>2?46 D4@C6] %96 E@@= FD6D G2C:@FD 724E@CD 7@C 42E68@C:K:?8 E96 A=2J6CD :?E@ 7@FC 42E68@C:6D] $@>6 @7 E96D6 724E@CD 4@?D:56C65 7@C 2?2=JD:D 2C6 7:?2?4:2= A6C7@C>2?46 @G6C E96 =2DE b J62CD[ 8C@HE9 DEC2E68:6D[ :??@G2E:@? D4@C6[ ?6H AC@5F4E =2F?496D[ :?G6DE>6?ED[ 8C@HE9 😕 >2C<6E D92C6[ 6E4]k^Am

kAmp?D@77 p?2=JD:Dk^Am

kF=mk=:m%96 C6A@CE AC6D6?ED 2 56E2:=65 p?D@77 >2EC:I 2?2=JD:D 7@C E96 v=@32= (9:E6 q:@E649?@=@8J |2C<6E] p?D@77 |2EC:I[ 2=D@ A2?J] %96 >2EC:I 42? 36 FD65 E@ 6G2=F2E6 2AAC@2496D 😕 7@FC DEC2E68:6D G:K] |2C<6E s6G6=@A>6?E[ |2C<6E !6?6EC2E:@?[ !C@5F4E s6G6=@A>6?E 2?5 s:G6CD:7:42E:@?] %96 >2EC:I 😀 2=D@ FD65 7@C C:D< 2?2=JD:D E@ F?56CDE2?5 E96 C:D< :?G@=G65 H:E9 6249 2AAC@249]k^=:mk=:m%96 v=@32= (9:E6 q:@E649?@=@8J |2C<6E :D 2?2=JK65 FD:?8 E96 p?D@77 |2EC:I E@ AC@G:56 E96 36DE 2AAC@2496D 2 4@>A2?J 42? E2<6 E@ :>AC@G6 :ED >2C<6E A@D:E:@?]k^=:mk=:mq2D65 @? E96 $(~% 2?2=JD:D 4@?5F4E65 @? E96 :?5FDECJ 2?5 :?5FDECJ A=2J6CD[ DF:E23=6 DEC2E68:6D 92G6 366? 56G:D65 7@C >2C<6E 8C@HE9]k^=:mk^F=m

kAm(9J qFJ %9:D #6A@CEnk^Am

kF=mk=:m%96 C6A@CE @776CD 2 4@>AC696?D:G6 6G2=F2E:@? @7 E96 v=@32= (9:E6 q:@E649?@=@8J |2C<6E] %96 C6A@CE :?4=F56D :?56AE9 BF2=:E2E:G6 2?2=JD:D[ G6C:7:23=6 52E2 7C@> 2FE96?E:4 D@FC46D[ 2?5 AC@;64E:@?D 23@FE >2C<6E D:K6] %96 AC@;64E:@?D 2C6 42=4F=2E65 FD:?8 AC@G6? C6D62C49 >6E9@5@=@8:6D]k^=:mk=:m%96 C6A@CE 92D 366? 4@>A:=65 E9C@F89 6IE6?D:G6 AC:>2CJ 2?5 D64@?52CJ C6D62C49] %96 AC:>2CJ C6D62C49 😀 5@?6 E9C@F89 :?E6CG:6HD[ DFCG6JD[ 2?5 @3D6CG2E:@? @7 C6?@H?65 A6CD@??6= H:E9:? E96 :?5FDECJ]k^=:mk=:m%96 C6A@CE :?4=F56D 2? :?56AE9 >2C<6E 2?2=JD:D FD:?8 !@CE6CVD d 7@C46D >@56= 2?5 E96 p?D@77 |2EC:I] x? 255:E:@?[ E96 :>A24E @7 r~'xs`h @? E96 >2C<6E :D 2=D@ 762EFC65 :? E96 C6A@CE]k^=:mk=:m%96 C6A@CE 2=D@ :?4=F56D E96 C68F=2E@CJ D46?2C:@ H:E9:? E96 :?5FDECJ[ H9:49 H:== 96=A J@F >2<6 2 H6==:?7@C>65 564:D:@?] %96 C6A@CE 5:D4FDD6D >2;@C C68F=2E@CJ 3@5:6D 2?5 >2;@C CF=6D U2>Aj C68F=2E:@?D :>A@D65 @? E9:D D64E@C 24C@DD G2C:@FD 86@8C2A9:6D]k^=:mk=:m%96 C6A@CE 2=D@ 4@?E2:?D 4@>A6E:E:G6 2?2=JD:D FD:?8 V!@D:E:@?:?8 "F25C2?EDVj 2 AC@AC:6E2CJ 4@>A6E:E:G6 A@D:E:@?:?8 E@@=]k^=:mk^F=m

kAm|2C<6E sJ?2>:4Dk^Am

kAmsC:G6CDk^Am

kF=mk=:mx?4C62D:?8 56>2?5 7@C q:@7F6=D 2?5 vC66? r96>:42=Dk^=:mk=:mr@DE 2?5 t?6C8J r@?DF>AE:@? p5G2?E286 r@>A2C65 E@ ~E96C %649?@=@8:6Dk^=:mk^F=m

kAm#6DEC2:?EDk^Am

kF=mk=:m{@H6C p5@AE:@? @7 q:@76CE:=:K6CD 2?5 q:@7F6=Dk^=:mk=:mt?G:C@?>6?E2= r@?D6BF6?46D @7 v6?6E:4 t?8:?66C:?8k^=:mk^F=m

kAm~AA@CEF?:E:6Dk^Am

kF=mk=:mx?4C62D:?8 x?G6DE>6?E 😕 q:@7F6=Dk^=:mk=:mq:@DJ?E96D:D @7 }2?@>2E6C:2=D 3J |:4C@@C82?:D>Dk^=:mk=:mq2? @? E96 &D6 @7 r@?G6?E:@?2= !=2DE:4k^=:mk=:mp5G2?46>6?E 😕 (9:E6 q:@E649?@=@8J %9C@F89 uF?8:k^=:mk^F=m

kAmr92==6?86Dk^Am

kF=mk=:mpG2=:3=:EJ @7 E96 p=E6C?2E:G6Dk^=:mk=:m$9:7E:?8 r@?DF>6C !C676C6?46Dk^=:mk=:m{:76 $A2? 2?5 {:>:E2E:@? @7 !C@5F4EDk^=:mk^F=m

kAmz6J %@A:4D r@G6C65ik^Am

kAm` #6A@CE s6D4C:AE:@?k^Am

kAma #6D62C49 |6E9@5@=@8Jk^Am

kAmb tI64FE:G6 $F>>2CJk^Am

kAmc |2C<6E sJ?2>:4Dk^Am

kAmd |2C<6E p?2=JD:Dk^Am

kAme v=@32= (9:E6 q:@E649?@=@8J |2C<6E[ 3J !C@5F4Ek^Am

kAmf v=@32= (9:E6 q:@E649?@=@8J |2C<6E[ 3J pAA=:42E:@?k^Am

kAmg p>6C:42DV (9:E6 q:@E649?@=@8J |2C<6Ek^Am

kAmh tFC@A6VD (9:E6 q:@E649?@=@8J |2C<6Ek^Am

kAm`_ |:55=6 t2DE 2?5 p7C:42VD (9:E6 q:@E649?@=@8J |2C<6Ek^Am

kAm`` p!prVD (9:E6 q:@E649?@=@8J |2C<6Ek^Am

kAm`a r@>A6E:E:G6 {2?5D42A6k^Am

kAm`b r@>A2?J !C@7:=6Dk^Am

kAm`c pAA6?5:Ik^Am

kAmr@>A2?:6D |6?E:@?65k^Am

kF=mk=:mpJC:Dk^=:mk=:mpC496C s2?:6=D |:5=2?5 r@>A2?Jk^=:mk=:mqp$uk^=:mk=:mq:@DA96C6k^=:mk=:mr2C8:==k^=:mk=:mr@C3:@?k^=:mk=:ms$|k^=:mk=:msF !@?E s2?:D4@k^=:mk=:muF;:7:=>k^=:mk=:mvt w62=E942C6k^=:mk=:mw6?<6=k^=:mk=:mw:E249: |65:42=k^=:mk=:mw@=@8:4k^=:mk=:m:rps >65k^=:mk=:mx?':G@ w62=E942C6k^=:mk=:ms$|k^=:mk=:m{6D277C6k^=:mk=:m|4z6DD@?k^=:mk=:m|6C86 w62=E942C6 Wxq|Xk^=:mk=:m}@G@KJ>6k^=:mk=:m!9:=:AD w62=E942C6k^=:mk=:m$:6>6?D w62=E942C6k^=:mk^F=m

kAmu@C >@C6 :?7@C>2E:@? 23@FE E9:D C6A@CE G:D:E k2 9C67lQ9EEADi^^HHH]C6D62C492?5>2C<6ED]4@>^C6A@CED^ded_gdc^8=@32=H9:E63:@E649?@=@8J>2C<6Ea_aaa_af3JnFE>0D@FC46lq(U2>AjFE>0>65:F>l!C6DD#6=62D6U2>AjFE>04@56l;fG?fEU2>AjFE>042>A2:8?l`fdbcbgZZv=@32=Z(9:E6Zq:@E649?@=@8JZ|2C<6EZ#6A@CEZa_aaTb2Zx?4C62D:?8Z56>2?5Z7@CZq:@7F6=DZ2?5ZvC66?Zr96>:42=DZsC:G6DZvC@HE9U2>AjFE>06I64l4@>@baaAC5Q C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^HHH]C6D62C492?5>2C<6ED]4@>^C^Hf2Fg?k^2mk^Am

kAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_haa__ddba^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_haa__ddba^6?^k^2mk^Am

kAmr~}%pr%i k2 9C67lQ9EEAi^^#6D62C49p?5|2C<6ED]4@>Qm#6D62C49p?5|2C<6ED]4@>k^2mk^Am

kAm{2FC2 (@@5[ $6?:@C !C6DD |2?286Ck^Am

kAmk2 9C67lQ>2:=E@iAC6DDoC6D62C492?5>2C<6ED]4@>QmAC6DDoC6D62C492?5>2C<6ED]4@>k^2mk^Am

kAmu@C t]$]% ~77:46 w@FCD r2== `h`fb___cf_k^Am

kAmu@C &]$]^ rp} %@== uC66 r2== `g__daegeb_k^Am

kAmu@C v|% ~77:46 w@FCD r2== Zbdb`c`egh__k^Am

kAmzt*(~#sik^Am

kAmx}s&$%#* zt*(~#si wtp{%w qx~%trw}~{~v*k^Am

kAm$~&#rti #6D62C49 2?5 |2C<6EDk^Am

kAmr@AJC:89E qFD:?6DD (:C6 a_aa]k^Am

kAm!&qi _h^aa^a_aa _fiaf p|^sx$ri _h^aa^a_aa _fiaf p|k^Am

kAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_haa__ddba^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_haa__ddba^6?k^2mk^Am

See more here:
Global White Biotechnology Market Report 2022: Increasing demand for Biofuels and Green Chemicals Drives Growth - ResearchAndMarkets.com - Oil City...

KAOHSIUNG, Taiwan, Sept. 19, 2022 /PRNewswire/ --Taiwan-based Anyong Biotechnology, has created a locally-sourced Sant Silver Perch Essence out of ecologically farmed, certified, and traceable silver perch in major markets such as Taiwan, the United States, Singapore, and Malaysia. As consumers' demands have for the product in the health and wellness industry are increasing, Anyong Biotechnology has developed a product from the nutrition-filled sea bass essence to maximize the benefits of sea bass on the human body.

The company has found its own golden ratio after consistent experimentation in the laboratory, which is not just on sea bass soup, but also extracted from various parts of the sea bass to create the incredible, bio-beneficial Silver Perch Essence.

Anyong Biotechnology's 'Sant Silver Perch Essence' is safe, scalable and in-demand

The global wellness economy was valued at $4.9 trillion in 2019 and is projected to have a 9.9% average annual growth, with the wellness economy predicted to reach nearly $7.0 trillion in 2025.

The Sant Silver Perch Essence has been confirmed by research to have incredible nutritional value with a higher absorption efficiency rate. It contains 18 kinds of amino acids and small molecule peptides which can be directly absorbed into the small intestine. It can also be used as a fast and effective supplement for all kinds of people from pregnant and breastfeeding mothers who require sufficient nutrition during pregnancy and postnatal nourishment, as well as patients who are recovering from an operation. The Silver Perch Essence is equally beneficial to sports players, office workers, and those who face difficulties in absorbing nutrients and vitamins.

Anyong Biotechnology has selected the Sant Silver Perch Essence with its production and sales history while ensuring that the source is non-toxic and safe to pass. The fish fingerlings are farmed from the Gaoping area with the cooperations and collaborations with high-quality local operators as well as young farmers. The result is a complete process of quality control from production, feed, and breeding which is used to enhance the resistance of aquatic products with probiotics. Furthermore, it has also been tested for no drug residues to ensure safety.

Development through an award-winning technology

Sticking with their principles of serving fresh food, Anyong Biotechnology uses a technology called CAS which enables a long-term storage of freshness for perch. This process was initially impossible with just conventional quick freezing.

Anyong Biotechnology combines CAS's rapid freezing and fresh-keeping technology with the technological advantages of its parent group Topco, and uses biotechnology procedures to extract the nutritional essence of fish meat, fish bones, and fish scales, and decompose them into small molecular peptides and amino groups.

The Ministry of Health and Welfare has recognized the Sant Silver Perch Essence for relieving physical fatigue resulting in Anyong Biotechnology winning the Gold Award of European Quality Evaluation Award for five consecutive years. The company has also won the "Healthy Fresh Sea Bass Essence", Taiwan's first Gold Award-winning sea bass essence product.

About Anyong Biotechnology

Anyong Biotechnology mission is to provide the highest level of aquatic food processing technology with a more stringent production environment, more advanced production facilities, and better-trained staff to serve clients seeking an aquatic food processing contractor at home or abroad, so as to contribute to the promotion of food quality and safety.

The company delivers a framework for food safety that incorporates everything from development and manufacturing to supply and distribution. Anyong Biotechnology's state-of-the-art fishery and seafood processing plant maintains a strict inspection procedure via its food safety centers, which monitor safety from the origin to the dining table every step of the way.

For more information, please visit https://anyong.en.taiwantrade.com/

Media Contact

ANYONG BIOTECHNOLOGY, INC.

Serene Sia

+886-2-7710-3192

serene.sia@anyongbio.com

Source: ANYONG BIOTECHNOLOGY, INC.

More:
Anyong Biotechnology's Locally Sourced 'Sant Silver Perch Essence' Fulfilling Increasing Demand in The APAC Wellness Industry - PR Newswire APAC - PR...

SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.

Nautilus co-founder and CEO Sujal Patel is scheduled to participate in the following two executive panel discussions:

Interested parties may contact kristen.patrick@capitalone.com to register to attend the virtual event.

About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit http://www.nautilus.bio.

Media Contactpress@nautilus.bio

Investor Contactinvestorrelations@nautilus.bio

Read more:
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit - GlobeNewswire